Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Teucrium Corn Fund (CORN) vs Zoetis Inc (ZTS) Price & Performance

Teucrium Corn FundTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Teucrium Corn Fund vs Zoetis Inc — how do they compare? Teucrium Corn Fund trades at $17.51, while Zoetis Inc trades at $74.5 (market cap $31.61B). The key difference: Zoetis Inc pays a 2.81% dividend while Teucrium Corn Fund pays none, and Teucrium Corn Fund is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.

CORNZTS
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$19.12$156.76
52-Week Low
$16.46$71.91
Market Cap
$31.61B
Enterprise Value
$38.90B
Dividend Yield
2.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Teucrium Corn Fund

No Aura AI signal available yet.

Zoetis Inc

Zoetis (ZTS) trades at $75.39, down 0.22% with bearish technical signals and mixed sentiment. The company maintains strong fundamentals with $9.47B revenue, 28.03% net margin, and robust profitability metrics (ROE 67.75%, ROA 18.27%). Recent Q1 2026 earnings missed expectations, while multiple law firms have filed class action lawsuits alleging securities violations between January 2025 and May 2026.

Despite strong financials and analyst consensus price target of $101.43 (34.5% upside), ZTS faces significant legal risks and technical weakness. The stock presents a value opportunity for long-term investors willing to navigate near-term volatility, though the class action lawsuits create substantial uncertainty for shareholder value.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Teucrium Corn Fund

CORN is a commodity ETF that provides exposure to the price of corn futures. It uses a laddered investment strategy across multiple benchmark contracts to help minimize the impact of contango and roll costs in the agricultural market.

Read more on CORN

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS